Prestin as an Early Biomarker of Hearing Loss in Nasopharyngeal Cancer Patients Undergoing Induction Chemoradiation

<b>Background/Objectives:</b> Nasopharyngeal cancer (NPC) is prevalent in Southeast Asia, Southern China and North Africa. Up to 46% of NPC patients undergoing cisplatin chemoradiation treatment experience irreversible hearing loss. Prestin is a motor protein in the outer hair cells of the cochlea,...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Vanessa Y. J. Tan, Ng Jia Hui, Kiattisa Sommat, Thong Jiun Fong, Edward Z. Y. Zhang, Lai Oi Fah, Chia Xin Ni, Ang Mei Kim, Ong Ni Gin, Lim Chwee Ming
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	MDPI AG 2026-03-01
Serie:	Journal of Otorhinolaryngology, Hearing and Balance Medicine
Soggetti:	ototoxicity biomarker cancer prestin hearing loss tinnitus
Accesso online:	https://www.mdpi.com/2504-463X/7/1/14
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!